Nucleic acids and polypeptides useful for diagnosing...

Details Nucleic acids and polypeptides useful for diagnosing... Nucleic acids and polypeptides useful for diagnosing...

2011-06-07

2011-06-07

Cheu, Jacob (Department: 1641)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C436S518000

Reexamination Certificate

active

07955805

ABSTRACT:
Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5238819 (1993-08-01), Roberts et al.
patent: 5240848 (1993-08-01), Keck et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5543138 (1996-08-01), Keith
patent: 5660827 (1997-08-01), Thorpe et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5830879 (1998-11-01), Isner
patent: 5928641 (1999-07-01), Seon
patent: 5958715 (1999-09-01), Muller
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6258787 (2001-07-01), Isner
patent: 6361946 (2002-03-01), Alitalo et al.
patent: 6365157 (2002-04-01), Rockwell et al.
patent: 6376199 (2002-04-01), Caniggia et al.
patent: 6399585 (2002-06-01), Larson et al.
patent: 6410322 (2002-06-01), Robinson
patent: 6447768 (2002-09-01), Van Zonneveld et al.
patent: 6620590 (2003-09-01), Groome et al.
patent: 6660534 (2003-12-01), McVicker et al.
patent: 6677300 (2004-01-01), Schreiner et al.
patent: 7191068 (2007-03-01), Rosenfeld et al.
patent: 7323346 (2008-01-01), Thadhani et al.
patent: 7344892 (2008-03-01), Thadhani et al.
patent: 2001/0055781 (2001-12-01), Groome et al.
patent: 2003/0114412 (2003-06-01), Ward et al.
patent: 2003/0144298 (2003-07-01), Curwen et al.
patent: 2003/0220262 (2003-11-01), Schreiner et al.
patent: 2004/0038305 (2004-02-01), Poston et al.
patent: 2004/0126828 (2004-07-01), Karumanchi et al.
patent: 2005/0025762 (2005-02-01), Karumanchi et al.
patent: 2005/0148040 (2005-07-01), Thadhani et al.
patent: 2005/0170444 (2005-08-01), Karumanchi et al.
patent: 2005/0266409 (2005-12-01), Brown et al.
patent: 2006/0067937 (2006-03-01), Karumanchi et al.
patent: 2006/0183175 (2006-08-01), Buhimschi et al.
patent: 2007/0104707 (2007-05-01), Karumanchi et al.
patent: 0 359 274 (1990-03-01), None
patent: 1 417 971 (2004-05-01), None
patent: WO 98/28006 (1998-07-01), None
patent: WO 02/37120 (2002-05-01), None
patent: WO 2004/008946 (2004-01-01), None
patent: WO 2005/077007 (2005-08-01), None
patent: WO 2006/034507 (2006-03-01), None
patent: WO 2006/069373 (2006-06-01), None
patent: WO 2008/030283 (2008-03-01), None
Milkiewicz et al. J. Physiology 2006, vol. 577, p. 671-678.
Schedel et al. Ann Rheum Dis 2004 vol. 63, p. 1205-1211.
Nishizawa et al. Molecular Human Reproduction 2008, vol. 14, p. 595-602.
Velzing-Aarts et al. Am J Rep Immu 2002 vol. 48, p. 319-322).
Baker et al., “Elevated Serum Levels of Vascular Endothelial Growth Factor in Patients with Preeclampsia,”Obstet. Gynecol.86: 815-821 (1995).
Davis-Smyth et al., “The Second Immunoglobulin-Like Domain of the VEGF Tyrosine Kinase Recpetor Flt-1 Determines Ligand Binding and May Initiate a Signal Transduction Cascade,”EMBO J.15: 4919-4927 (1996).
Davis-Smyth et al., “Mapping the Charged Residues in the Second Immunoglobulin-Like Domain of the Vascular Endothelial Growth Factor/Placenta Growth Factor Receptor Flt-1 Required for Binding and Structural Stability,”J. Biol. Chem.273: 3216-3222 (1998).
Dvorak, “Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy,”J. Clin. Oncol.20: 4368-4380 (2002).
Errico et al., “Identification of Placenta Growth Factor Determinants for Binding and Activation of Flt-1 Receptor,”J. Biol. Chem. 279: 43929-43939 (2004).
Ferrara, “Role of Vascular Endothelial Growth Factor in Regulation of Physiological Angiogenesis,”Am. J. Physiol. Cell Physiol.280: C1358-C1366 (2001).
Florio et al., “Inhibins and Activins in Pregnancy,”Mol. Cell. Endocrinol.225: 93-100 (2004).
Hsieh, “Maternal Serum Placenta Growth Factor and Vascular Endothelial Growth Factor in Pregnancies Complicated by Preeclampsia (Abstract),”Am. J. Obstet. Gynecol.184: S70 (2001).
Iyer et al., “The Crystal Structure of Human Placenta Growth Factor-1 (PIGF-1), an Angiogenic Protein, at 2.0 Å Resolution,”J. Biol. Chem.276: 12153-12161 (2001).
Keyt et al., “Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors,”J. Biol. Chem.271: 5638-5646 (1996).
Krauss et al, “Circulating Endothelial Cell Adhesion Molecules as Diagnostic Markers for the Early Identification of Pregnant Women at Risk for Development of Preeclampsia,”Am. J. Obstet. Gynecol.177: 443-449 (1997).
Krussel et al., “Expression of mRNA for Vascular Endothelial Growth Factor Transmembraneous Recpetors Flt1 and KDR, and the Soluble Receptor sflt in Cycling Human Endometrium,”Mol. Hum. Reprod.5: 452-458 (1999).
Li et al., “Recombinant VEGF121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia,”Hypertension092098 (2007).
Lyall et al., “Suppression of Serum Vascular Endothelial Growth Factor Immunoreactivity in Normal Pregnancy and in Pre-Eclampsia,”BJOG104: 223-228 (1997).
Maynard et al., “Sflt-1, a Circulating VEGF Antagonist, is Up-Regulated in Preeclampsia and Contributes to Endothelial Dysfunction,”J. Am. Soc. Nephrol.13: SU-FC280 (2002).
Moran et al., “Glomerular Ultrafiltration in Normal and Preeclamptic Pregnancy,”J. Am. Soc. Nephrol.14: 648-652 (2003).
Muller et al., “The Crystal Structure of Vascular Endothelial Growth Factor (VEGF) Refined to 1.93 Å Resolution: Multiple Copy Flexibility and Receptor Binding,”Structure5: 1325-1338 (1997).
Muller et al., “Vascular Endothelial Growth Factor: Crystal Structure and Functional Mapping of the Kinase Domain Receptor Binding Site,”Proc. Natl. Acad. Sci. USA94: 7192-7197 (1997).
Nishizawa et al., “Increased Levels of Pregnancy-Associated Plasma Protein-A2 in the Serum of Pre-Eclamptic Patients,”Mol. Hum. Reprod. 14: 595-602 (2008).
Oswald et al., “Mesanchymal Stem Cells Can Be Differentiated into Endothelial Cells In Vitro,”Stem Cells22: 377-384 (2004).
Olofsson et al., “Vascular Endothelial Growth Factor B (VEGF-B) Binds to VEGF Receptor-1 and Regulates Plasminogen Activator Activity in Endothelial Cells,”Proc. Natl. Acad. Sci. USA95: 11709-11714 (1998).
Park et al., “Placenta Growth Factor: Potentiation of Vascular Endothelial Growth Factor Bioactivity, In Vitro and In Vivo, and High Affinity Binding to Flt-1 but not to Flk-1/KDR,”J. Biol. Chem.269: 25646-25654 (1994).
Park et al., “An Elevated Maternal Plasma, but not Amniotic Fluid, Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) at the Time of Mid-Trimester Genetic Amniocentesis is a Risk Factor for Preeclampsia,”Am. J. Obstet. Gynecol.1

Affiliated with

Also associated with

Rating

Nucleic acids and polypeptides useful for diagnosing... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleic acids and polypeptides useful for diagnosing..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleic acids and polypeptides useful for diagnosing... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2683439